For: | Herold Z, Herold M, Herczeg G, Fodor A, Szasz AM, Dank M, Somogyi A. High plasma CD40 ligand level is associated with more advanced stages and worse prognosis in colorectal cancer. World J Clin Cases 2022; 10(13): 4084-4096 [PMID: 35665117 DOI: 10.12998/wjcc.v10.i13.4084] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v10/i13/4084.htm |
Number | Citing Articles |
1 |
Zijing Wang, Zhanyuan Sun, Hengyi Lv, Wenjun Wu, Hai Li, Tao Jiang. Machine learning-based model for CD4+ conventional T cell genes to predict survival and immune responses in colorectal cancer. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-75270-y
|
2 |
Shanshan Ding, Xiaohan Dong, Xingguo Song. Tumor educated platelet: the novel BioSource for cancer detection. Cancer Cell International 2023; 23(1) doi: 10.1186/s12935-023-02927-5
|
3 |
Matjaz Rokavec, Elif Özcan, Jens Neumann, Heiko Hermeking. Development and Validation of a 15-gene Expression Signature with Superior Prognostic Ability in Stage II Colorectal Cancer. Cancer Research Communications 2023; 3(8): 1689 doi: 10.1158/2767-9764.CRC-22-0489
|
4 |
Hiroshi Fujimoto, Soichiro Fukuzato, Kazuki Kanno, Taisuke Akutsu, Hironori Ohdaira, Yutaka Suzuki, Mitsuyoshi Urashima. Reduced Relapse-Free Survival in Colorectal Cancer Patients with Elevated Soluble CD40 Ligand Levels Improved by Vitamin D Supplementation. Nutrients 2023; 15(20): 4361 doi: 10.3390/nu15204361
|
5 |
Cheng-Zhe Jian, Li Lin, Chia-Lang Hsu, Yu-Hsin Chen, Chiun Hsu, Ching-Ting Tan, Da-Liang Ou. A potential novel cancer immunotherapy: Agonistic anti-CD40 antibodies. Drug Discovery Today 2024; 29(3): 103893 doi: 10.1016/j.drudis.2024.103893
|
6 |
Alireza Pazoki, Sepehr Dadfar, Alireza Shadab, Dariush Haghmorad, Valentyn Oksenych. Soluble CD40 Ligand as a Promising Biomarker in Cancer Diagnosis. Cells 2024; 13(15): 1267 doi: 10.3390/cells13151267
|
7 |
Juan Zhang, Lei Wang, Shuyi Li, Xuefeng Gao, Zhong Liu. CD40 monoclonal antibody and OK432 synergistically promote the activation of dendritic cells in immunotherapy. Cancer Cell International 2022; 22(1) doi: 10.1186/s12935-022-02630-x
|